{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-059356","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.802680+00:00","generated_at":"2026-06-05T04:02:02.337407+00:00","sec_items":["1.01","3.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Sensei Biotherapeutics extends stockholder rights plan to March 2025, removes 'acting in concert' definition","bullets":["Second Amendment to Rights Agreement extends expiration date to March 7, 2025 (from March 7, 2024).","The amendment eliminates the 'acting in concert' beneficial ownership provision from the Rights Agreement.","Rights remain subject to earlier redemption, exchange, or termination per the agreement.","Amendment is between Sensei Biotherapeutics and Equiniti Trust Company, LLC, as Rights Agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-059356","json":"https://secwatch.observer/filing/0001193125-24-059356.json","markdown":"https://secwatch.observer/filing/0001193125-24-059356.md","text":"https://secwatch.observer/filing/0001193125-24-059356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524059356/0001193125-24-059356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524059356/d792997d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:02:02.337407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}